SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival Cytarabine (Ara-C) is the most important element of standard acute myeloid leukemia (AML) treatment regimens since more than 40 years. However, response to Ara-C treatment is marked by significant inter-individual differences and the development of Ara-C resistance is still a major drawback. Differences in DNA sequences, such as single nucleotide polymorphisms (SNPs), may affect the expression and/or function of specific drug protein targets and explain, at least in part, the interindividual variations in the response to specific treatments.
Ara-C is a deoxycytidine analog, which blocks DNA synthesis. 1 Key enzymes within the Ara-C metabolic pathway are the deoxycytidine kinase (DCK), which is important for Ara-C activation and two enzymes that regulate Ara-C degradation: cytidine deaminase (CDA), which catalyses the conversion of Ara-C into inactive Ara-U, and deoxycytidylate deaminases (DCTD), which catalyses the conversion of Ara-CMP into inactive Ara-UMP. 1 The phosphorylation of Ara-C into Ara-CMP by DCK 2 is the rate limiting step for Ara-C activation and is followed by conversion into Ara-CTP, which then competes with dCTP for incorporation into DNA and subsequent block of DNA synthesis ( Figure 1 ). 1, 2 In this study, we identified and correlated SNPs of these three critical enzymes within the Ara-C metabolic pathway with drug-induced toxicity and 5-year overall survival (OS) in 360 caucasian AML patients. All the patients were treated within the multicenter trial AML96 of the German Study Initiative Leukemia (DSIL) between 1996 and 2003 (patient characteristics: Table 1 ). Median observation time was 6.2 (4.3-9.0) years. AML FAB-M3 (acute promyelocytic leukemia (APL)) patients were not included and treated in other European trials.
The study was approved by the responsible national ethics committees and was in agreement with the declaration of Helsinki and registered with the NCT number 00180115. Written informed consent was given by all the patients. The treatment schedule was published earlier. 3 Briefly, in individuals aged 60 years or younger, first induction therapy consisted 2 every 12 h days 1-6)(I-MAC) or high-dose (2 Â 3000 mg/m 2 every 12 h days 1-6)(H-MAC) Ara-C þ mitoxantrone (10 mg/m 2 day 4 to 6), which was followed by autologous PBSCT (intermediate cytogenetic risk) or MAMAC (low cytogenetic risk). Patients with high-risk cytogenetics were referred to allogeneic hematopoietic stem cell transplantation including the option of unrelated hematopoietic stem cell transplantation. Patients over 60 years of age received two induction cycles containing daunorubicin 45 mg/m 2 (days 3-5) and Ara-C 100 mg/m 2 (days 1-7) ( ¼ DA). Patients in complete remission (CR) received MAMAC (see above). All patient material (bone marrow/peripheral blood) was obtained at the time of diagnosis. Genomic DNA was extracted from mononuclear cells after density gradient centrifugation (BIOCOLL, Biochrom, Berlin Germany). For the discrimination of CD34-positive cells, CD34 monoclonal antibody QBEnd10 (Coulter, Hamburg, Germany) was used according to the earlier published protocols. 4 Analyses of FLT3-ITD 5 and NPM1 5, 6 mutations and chromosome analyses were carried out as published earlier. 7 Cytogenetic risk groups are as follows: unfavorable: À5/del(5q), À7/del(7q), hypodiploid karyotypes (besides 45,X,ÀY or -X), inv(3q), abnl12p, abnl11q, þ 11, þ 13, þ 21, þ 22, t(6;9); t(9;22); t(9;11); t(3;3), multiple aberrations; intermediate: patients without low-risk or high-risk constellation; favorable: t(8;21) and t(8;21) combined with other aberrations. To identify SNPs in the three key enzymes of Ara-C metabolism (Figure 1 ), we carried out in silico analyses with three SNP databases: dbSNP (NIH), 8 HapMap 9 and ABI (Applied Biosystems, Foster City, CA, USA). 10 Analyses were focused on coding, nonsynonymous SNPs, which can influence protein structure, activity, stability or localization because of change of the amino acid sequence and on promoter SNPs, which can lead to changes in expression levels. Known, validated SNPs from the literature were also included.
Validation of identified SNPs was carried out through allele-specific SNP-Assays by TaqMan-PCR on an ABI Prism 7700 Sequence Detection System (ABI, Darmstadt, Germany) in accordance with the instructions provided by the manufacturer.
Our analyses confirmed a number of SNPs within the DCK (C364T ¼ SNP7) and
) were identified to be either false positives or not present in caucasians, showing only wild-type allele ( Figure 2a and Table 2 ). SNP3 G208A could not be confirmed in our study in concordance with Fitzgerald et al., who did not detect this SNP in caucasians either. Two additional DCK promoter SNPs (C-360G and C-201T) could not be analyzed because of failure in manufacturing.
Differences in clinical or laboratory parameters were compared between SNPs using the Mann-Whitney test for continuous and the w 2 -test for categorical variables. OS was calculated from the date of diagnosis until death (failure) or last follow-up date (censored). Disease-free survival was measured from the date of documented CR to relapse (failure), to death in CR (failure) or to alive in CR at last follow-up (censored). The Kaplan-Meier method was used to estimate survival probabilities, which were compared between different groups using the log rank test. The Cox model was applied to identify independent prognostic variables for survival. A stepwise backward-selection procedure was carried out to determine the final model. The significance level was 0.05. To provide quantitative information on the relevance of results, 95% CIs of odds ratios and hazard ratios were computed. Statistical analyses were carried out with the SPSS (SPSS Inc., Chicago, IL, USA) and the S-PLUS programs (Insightful AG, Reinach, Switzerland). The deviation from the Hardy-Weinberg Equilibrium for the three relevant SNPs (CDA SNP1, SNP4 and SNP 5) with significant patient numbers in all three possible genotypes was tested using the w 2 -test. For pairwise linkage disequilibrium between the genetic markers three estimators, D, D 0 and r were computed. These analyses were carried out using the free statistical computing environment R (Version 2.3.1) and its library genetics for genetic analyses.
Genotype frequencies were analyzed in the all patients for CDA SNP1-6 and DCK SNP7-8 and DCTD SNP9 (Figure 2a , Table 2 ). CDA SNP1, SNP4 and SNP5 frequencies were in accordance with the Hardy-Weinberg prediction (P ¼ 0.82, P ¼ 0.65 and P ¼ 0.65, respectively). These three SNPs were in linkage disequilibrium to each other (Po0.0001 for each The CDA SNP1, SNP4 and SNP5 genotypes had no significant influence on WBC, RBC, platelet or bone marrow blast cell counts or CD34 expression at diagnosis. However, patients with the CDA SNP5 2_2-genotype had significantly higher lactate dehydrogenase levels when compared with the 1_2 or 1_1-genotypes (P ¼ 0.01), whereas no such difference was seen for the other two SNPs. Correlation with the molecular markers FLT3 and NPM1 revealed that the CDA SNP5 2_2-genotype was more frequently positive for FLT3-ITD mutation (46%) when compared with the genotypes 1_2 (26%) and 1_1 (26%) (P ¼ 0.03). No such differences were, however, seen for the other genotypes. Also, no imbalances were seen with respect to age, disease status, French-AmericanBritish (FAB) classification, Eastern Cooperative Oncology Group (ECOG) status or cytogenetic risk between the different genotypes.
The correlation of CDA SNP genotypes with Ara-C treatmentrelated toxicity (overall toxicities: 4/360 grade III/IV eye toxicity, 8/360 skin toxicity, 116/360 gastrointestinal toxicity, 62/360 liver toxicity, 20/360 central nervous system toxicity) showed that patients displaying a CDA SNP1 and SNP4 1_1-genotype had lower incidences for grade III/IV liver toxicity when compared with the respective 1_2 or 1_1-genotypes (13 vs 21 vs 23%; P ¼ 0.03 in the Cochrane-Mantel-Haenszel Test), whereas no significant correlation was observed with the other SNPs or SNP combinations and other types of toxicity.
Another aim of this study was to reveal whether there is any influence of CDA genotypes on treatment outcome. A total of 185/360 (51%) patients reached CR after Ara-C doubleinduction therapy. Whereas the CDA SNP1, SNP4 and SNP5 genotypes and their combinations had no significant influence on response to treatment, 5-year OS was worse for the CDA SNP5 2_2-genotype vs the 1_1-genotype (OS: 13 vs 25%, P ¼ 0.05). Differences in the 5-year disease-free survival were not statistically significant (2_2-genotype: 23%, 1_1-genotype 39%, P ¼ 0.08). Patients with the 1_2-genotype had an intermediate overall (23%) and disease-free (29%) survival (Figure 2b and c).
In the multivariate Cox analysis considering CDA SNP1 (SNP A79C), SNP4 (promoter SNP G-88A) and SNP5 genotype (promoter SNP C-451T), cytogenetic risk, WBC, platelet count, lactate dehydrogenase, CD34 expression, bone marrow blast count, NPM/FLT3 mutation status, age and disease status, the CDA SNP5 genotype proved to be an independent prognostic factor for survival: patients with the 2_2-genotype had a 450% increased risk for death compared with patients with the 1_1-genotype (hazard ratio 1.56 (95%-CI 1.09-2.24); P ¼ 0.02).
With these results of our study, we could reveal the clinical relevance of earlier findings of Fitzgerald et al., 12 who showed that the CDA promoter SNP C-451T functionally leads to reduction in the CDA expression level and the level of CDA enzymatic activity, which was already assumed to increase the risk of toxicity and adverse events associated with the standard dosage of Ara-C therapy, which is in accordance with our data. Despite Ara-C being the most important drug in AML therapy, patients receive a multiagent therapy including anthracyclines, mitoxantrone, amsacrine and etoposide in combination with Ara-C. Therefore, these other agents could have had some influence on liver toxicity and treatment response independent of the examined CDA SNPs.
Nevertheless, our results show that the CDA SNP C-451T is a significant, independent prognostic factor for survival, which further prompts the need for individualized chemotherapy in patients who are being given Ara-C or other nucleoside analogs.
